Internal Reference Number: FOI_8160
Date Request Received: 13/09/2024 00:00:00
Date Request Replied To: 01/10/2024 00:00:00
This response was sent via: By Email
Request Summary: intra-vitreal injections or implants
Request Category: Companies
| Question Number 1: How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2024: • Aflibercept • Bevacizumab - Avastin • Bevacizumab - Biosimilar • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - Lucentis (pre-filled syringes) • Ranibizumab - Lucentis (vials) • Ranibizumab - Ongavia • Ranibizumab – Ximluci | |
| Answer To Question 1: Aflibercept 1113 Bevacizumab - Avastin 11 Bevacizumab - Biosimilar 0 Brolucizumab 0 Dexamethasone 16 Faricimab 770 Fluocinolone acetonide 0 Ranibizumab - Lucentis (pre-filled syringes) 0 Ranibizumab - Lucentis (vials) 0 Ranibizumab - Ongavia 0 Ranibizumab – Ximluci 0 | |
| Question Number 2: Please provide the number of injections/implants by eye condition for the four-month period from May to August 2024: - see attached | |
| Answer To Question 2: Please see attached. To accompany this answer to question 2 please also see the documents listed below:  8160 Q2 Final.pdf | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
